Peripheral arterial rather than venous blood is a better source of circulating tumor cells in early lung cancer

Thorac Cancer. 2024 Mar;15(8):654-660. doi: 10.1111/1759-7714.15236. Epub 2024 Jan 31.

Abstract

Background: Circulating tumor cells (CTCs) play a crucial role in the early diagnosis and prognosis of lung cancer. Identification of a more suitable sample source could be a breakthrough towards enhancing CTC detectability in early-stage lung cancer. We investigated the differences in detectable CTCs between peripheral arterial and venous blood in early- and mid-stage lung cancer patients undergoing surgery and analyzed the association between clinicopathological factors and detectable CTCs in peripheral arterial and venous blood.

Methods: Peripheral arterial and venous blood was collected in 5-mL samples from 56 patients with surgically resected and pathologically clear at early- or mid-stage lung cancer. Blood specimens were enriched for CTCs based on isolation by size of epithelial tumor cells. The CTCs were identified using Swiss Giemsa staining and immunohistochemistry for CD45/CD31.

Results: In stage I lung cancer, CTC-positive rate was significantly higher in peripheral arterial than in venous blood (45.45% vs. 17.39%). There was no significant difference in the number of detectable CTCs between peripheral arterial and venous blood. A low degree of differentiation was associated with a high positive rate of CTCs in peripheral venous blood. The number of circulating tumor microemboli was significantly higher in patients with tumor size >3 cm compared with ≤3 cm.

Conclusion: CTC levels in peripheral arterial and venous blood differed little in lung cancer patients.Compared to peripheral venous blood, peripheral arterial blood had a higher CTC positivity rate in early-stage lung cancer.This study was favorable for early detection and monitoring of lung cancer.

Keywords: circulating tumor cells; lung cancer; peripheral arterial blood; peripheral venous blood; positivity rate.

MeSH terms

  • Biomarkers, Tumor
  • Humans
  • Lung Neoplasms* / pathology
  • Neoplastic Cells, Circulating* / pathology
  • Prognosis

Substances

  • Biomarkers, Tumor